Medicines planning
47 results
Applied filters
Annual medicines planning publication, Prescribing Outlook
12 January 2026Our annual output to support managed entry and budget planning for new medicines, new indications and patent expiries in the NHS.
Biosimilar and key generic medicines – December 2025 update
10 December 2025An update about biosimilar and key generic medicines to support system planning and mobilisation.
The licence and supporting evidence for ranibizumab biosimilars
5 November 2025Four licensed ranibizumab biosimilars are available: Byooviz, Ongavia, Rimmyrah and Ximluci. Learn about the licensed indications and supporting evidence
Preparing to use ranibizumab biosimilar
5 November 2025Ranibizumab biosimilar needs planning. Ensure you are familiar with the area and then develop an implementation plan working with the multidisciplinary team
The licence and supporting evidence for denosumab 60mg biosimilars
16 January 2026Denosumab 60mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.
The licence and supporting evidence for golimumab biosimilar
28 November 2025We highlight evidence for licensed golimumab biosimilar(s) and differences between the biosimilar(s) and the reference product (Simponi).
The licence and supporting evidence for denosumab 120mg biosimilars
16 January 2026Denosumab 120mg biosimilars are licensed. Learn about indications, formulations, supporting evidence and differences.